A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)

Stratum 1 (Adult GBM) * Age ≥ 21 years. * Histopathologically proven newly-diagnosed de novo GBM (WHO Grade IV glioma, secondary GBM not eligible) that is MGMT low level or unmethylated. * The tumor must have a supratentorial component. * Patient must have been enrolled on a screening consent and have had sterile collection of tumor material in a manner suitable for RNA extraction, amplification, and loading of lipid particles (LPs). * Residual post-surgical disease burden ≤ 3 cm as defined by longest perpendicular diameter of tumor on post-operative MRI. * Patients must have recovered from the effects of surgery, postoperative infection, and other complications. * A diagnostic contrast-enhanced MRI of the brain must be performed preoperatively and postoperatively. Pre-op MRI must be performed within 28 days prior to study enrollment. Post-op MRI must be completed within 7 days after surgery. Preoperative and postoperative scans must be the same type. * Performance Score: (KPS) ≥ 60. Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score. * Bone Marrow: * ANC (Absolute neutrophil count) ≥ 1,000µl (unsupported) * Platelets ≥ 150/µl (unsupported for at least 7 days) * Hemoglobin \> 8 g/dL * Renal: * BUN ≤ 25 mg/dl * Creatinine ≤ 1.7 mg/dl * Hepatic * Bilirubin ≤ 2.0 mg/dl * ALT ≤ 5 times institutional upper limits of normal for age * AST ≤ 5 ti…